Skye Bioscience Inc
NASDAQ:SKYE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Grahaprima Suksesmandiri Tbk PT
IDX:GTRA
|
ID |
|
W
|
Wetteri Oyj
OMXH:WETTERI
|
FI |
|
A
|
Astor Enerji AS
IST:ASTOR.E
|
TR |
|
Z
|
Zaigle Co Ltd
KOSDAQ:234920
|
KR |
|
Lipocine Inc
NASDAQ:LPCN
|
US |
|
Aeon Financial Service Co Ltd
TSE:8570
|
JP |
|
IDI SCA
PAR:IDIP
|
FR |
|
Poste Italiane SpA
MIL:PST
|
IT |
|
Volvo AB
STO:VOLV B
|
SE |
|
E
|
Elan Corp
TSE:6099
|
JP |
|
Pandox AB
STO:PNDX B
|
SE |
|
S
|
Super Copper Corp
CNSX:CUPR
|
CA |
|
Beijing Shengtong Printing Co Ltd
SZSE:002599
|
CN |
|
Cactus Inc
NYSE:WHD
|
US |
|
D
|
Daiichi Commodities Co Ltd
TSE:8746
|
JP |
|
Japan Securities Finance Co Ltd
TSE:8511
|
JP |
|
K
|
K. W. Metal Work PCL
SET:KWM
|
TH |
|
S
|
Selangor Dredging Bhd
KLSE:SDRED
|
MY |
|
Keong Hong Holdings Ltd
SGX:5TT
|
SG |
Skye Bioscience Inc
Research & Development
Skye Bioscience Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Skye Bioscience Inc
NASDAQ:SKYE
|
Research & Development
-$42.4m
|
CAGR 3-Years
-92%
|
CAGR 5-Years
-85%
|
CAGR 10-Years
-54%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Skye Bioscience Inc
Glance View
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
See Also
What is Skye Bioscience Inc's Research & Development?
Research & Development
-42.4m
USD
Based on the financial report for Dec 31, 2025, Skye Bioscience Inc's Research & Development amounts to -42.4m USD.
What is Skye Bioscience Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-54%
Over the last year, the Research & Development growth was -127%. The average annual Research & Development growth rates for Skye Bioscience Inc have been -92% over the past three years , -85% over the past five years , and -54% over the past ten years .
